Medicus Pharma CEO Highlights AI-Driven Drug Development on Bloomberg

Reuters

Feb 12

<a href="https://laohu8.com/S/MDPLD">Medicus Pharma</a> CEO Highlights AI-Driven Drug Development on Bloomberg

Dr. Raza Bokhari, Executive Chairman and CEO of Medicus Pharma Ltd. (NASDAQ:MDCX), appeared on Bloomberg World for a live interview with anchor Matt Miller. During the discussion, Dr. Bokhari outlined the company's AI-driven approach to accelerating drug development and highlighted how Medicus Pharma's leadership has committed nearly $14 million of personal capital at $4 per share to advance its pipeline. He expressed optimism that upcoming catalysts, including Phase 2 clinical data readouts for Skinject in the first half of 2026, would change investor perception and unlock significant value. The interview also addressed the challenges facing biotech stocks and the transformative potential of artificial intelligence in innovative therapy development. Click here to watch the full interview.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Medicus Pharma Ltd. published the original content used to generate this news brief via ACCESS Newswire (Ref. ID: 1136602) on February 12, 2026, and is solely responsible for the information contained therein.

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

1
2
3
4
5
6
7
8
9
10

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers | Global Stocks, Options & Futures Trading App","description":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","keywords":"tiger brokers,tiger trade,tiger brokers singapore,broker online,stock trading in singapore,share trading singapore,brokerage firm singapore,trading app,stock broker singapore,stock trading platforms,trading account","social":{"ogDescription":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/news/2610925119"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental"},"isCrawlerRequest":true,"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"2610925119\",edition:\"fundamental\",auth_exemption:1,,,undefined,":{"share":"https://ttm.financial/m/news/2610925119?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2026-02-12 20:30","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2610925119","market":"us","top_or_hot":-1,"title":"Medicus Pharma CEO Highlights AI-Driven Drug Development on Bloomberg","media":"Reuters","content":"<html xmlns=\"http://www.w3.org/1999/xhtml\" xmlns:newsg2=\"http://iptc.org/std/nar/2006-10-01/\" xmlns:xhtml=\"http://www.w3.org/1999/xhtml\"><head><title>\n      <a href=\"https://laohu8.com/S/MDPLD\">Medicus Pharma</a> CEO Highlights AI-Driven Drug Development on Bloomberg\n    </title></head><body><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<p>\n        Dr. Raza Bokhari, Executive Chairman and CEO of <a href=\"https://laohu8.com/S/MDCX\">Medicus Pharma Ltd.</a> (NASDAQ:MDCX), appeared on Bloomberg World for a live interview with anchor Matt Miller. During the discussion, Dr. Bokhari outlined the company's AI-driven approach to accelerating drug development and highlighted how <a href=\"https://laohu8.com/S/MDPLF\">Medicus Pharma</a>'s leadership has committed nearly $14 million of personal capital at $4 per share to advance its pipeline. He expressed optimism that upcoming catalysts, including Phase 2 clinical data readouts for Skinject in the first half of 2026, would change investor perception and unlock significant value. The interview also addressed the challenges facing biotech stocks and the transformative potential of artificial intelligence in innovative therapy development. Click here to watch the full interview.</p>\n</div><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<p>\n<i>Disclaimer: <span>This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Medicus Pharma Ltd. published the original content used to generate this news brief via ACCESS Newswire (Ref. ID: 1136602) on February 12, 2026, and is solely responsible for the information contained therein.</span></i>\n</p>\n</div></body></html>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Medicus Pharma CEO Highlights AI-Driven Drug Development on Bloomberg</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nMedicus Pharma CEO Highlights AI-Driven Drug Development on Bloomberg\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1032215980\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/4567337cbdf294b657b1fa87c5488b48);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Reuters </p>\n<p class=\"h-time\">2026-02-12 20:30</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<html xmlns=\"http://www.w3.org/1999/xhtml\" xmlns:newsg2=\"http://iptc.org/std/nar/2006-10-01/\" xmlns:xhtml=\"http://www.w3.org/1999/xhtml\"><head><title>\n      <a href=\"https://laohu8.com/S/MDPLD\">Medicus Pharma</a> CEO Highlights AI-Driven Drug Development on Bloomberg\n    </title></head><body><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<p>\n        Dr. Raza Bokhari, Executive Chairman and CEO of <a href=\"https://laohu8.com/S/MDCX\">Medicus Pharma Ltd.</a> (NASDAQ:MDCX), appeared on Bloomberg World for a live interview with anchor Matt Miller. During the discussion, Dr. Bokhari outlined the company's AI-driven approach to accelerating drug development and highlighted how <a href=\"https://laohu8.com/S/MDPLF\">Medicus Pharma</a>'s leadership has committed nearly $14 million of personal capital at $4 per share to advance its pipeline. He expressed optimism that upcoming catalysts, including Phase 2 clinical data readouts for Skinject in the first half of 2026, would change investor perception and unlock significant value. The interview also addressed the challenges facing biotech stocks and the transformative potential of artificial intelligence in innovative therapy development. Click here to watch the full interview.</p>\n</div><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<p>\n<i>Disclaimer: <span>This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Medicus Pharma Ltd. published the original content used to generate this news brief via ACCESS Newswire (Ref. ID: 1136602) on February 12, 2026, and is solely responsible for the information contained therein.</span></i>\n</p>\n</div></body></html>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"MDCX","symbol_name":"Medicus Pharma Ltd.","start_time":0,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260212:nNDL30Mxvv:1","article_id":"2610925119","we_media_id":"1032215980","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2610925119","pubTimestamp":1770899432,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Reuters","introduction":"Reuters.com brings you the latest news from around the world, covering breaking news in markets, business, politics, entertainment and technology","home_visible":1,"id":"1032215980","head_image":"https://community-static.tradeup.com/news/4567337cbdf294b657b1fa87c5488b48"},"summary":"Dr. Raza Bokhari, Executive Chairman and CEO of Medicus Pharma Ltd. , appeared on Bloomberg World for a live interview with anchor Matt Miller. During the discussion, Dr. Bokhari outlined the company's AI-driven approach to accelerating drug development and highlighted how Medicus Pharma's leadership has committed nearly $14 million of personal capital at $4 per share to advance its pipeline. He expressed optimism that upcoming catalysts, including Phase 2 clinical data readouts for Skinject in the first half of 2026, would change investor perception and unlock significant value. The interview also addressed the challenges facing biotech stocks and the transformative potential of artificial intelligence in innovative therapy development. Click here to watch the full interview.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for information","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"MDCX":"Medicus Pharma Ltd.","BK4139":"生物科技"},"translate_title":"Medicus Pharma首席执行官在彭博社强调人工智能驱动的药物开发","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"MDCX":0.9},"content_text":"Medicus Pharma CEO Highlights AI-Driven Drug Development on Bloomberg\n    \n\n        Dr. Raza Bokhari, Executive Chairman and CEO of Medicus Pharma Ltd. (NASDAQ:MDCX), appeared on Bloomberg World for a live interview with anchor Matt Miller. During the discussion, Dr. Bokhari outlined the company's AI-driven approach to accelerating drug development and highlighted how Medicus Pharma's leadership has committed nearly $14 million of personal capital at $4 per share to advance its pipeline. He expressed optimism that upcoming catalysts, including Phase 2 clinical data readouts for Skinject in the first half of 2026, would change investor perception and unlock significant value. The interview also addressed the challenges facing biotech stocks and the transformative potential of artificial intelligence in innovative therapy development. Click here to watch the full interview.\n\n\nDisclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Medicus Pharma Ltd. published the original content used to generate this news brief via ACCESS Newswire (Ref. ID: 1136602) on February 12, 2026, and is solely responsible for the information contained therein.","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"1","news_tag":"","news_rank":0,"symbols":[],"gpt_button":0,"need_auth":false,"code":"91000000","status":"200"}}}